Erin Dorn
Medical · Beatrice, NENPI 1144610197
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 29.2% of the total. 2025 is the largest year on record at $804, 5.1 times the $158 reported in 2021.
Across 112 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$568
- Novartis$208
- Novo Nordisk$186
- Pfizer$180
- Amgen$171
- Boehringer Ingelheim$111
- plus $525 from 16 others
What the payments were for
- Food & beverage$1,949100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $568 |
| Novartis | 12 | $208 |
| Novo Nordisk | 12 | $186 |
| Pfizer | 12 | $180 |
| Amgen | 9 | $171 |
| Boehringer Ingelheim | 2 | $111 |
| Astellas Pharma US Inc | 3 | $99 |
| AstraZeneca | 4 | $60 |
| Abbott | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| Insulet Corporation | 2 | $42 |
| Johnson & Johnson | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Bayer | 2 | $28 |
| Lilly USA, LLC | 2 | $27 |
| Organon | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$1,949 in reported general payments places this provider in the 80th percentile of 216 medical providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $83,397 |
| OzempicSemaglutide | 62 | $72,923 |
| XareltoRivaroxaban | 66 | $55,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $52,982 |
| EliquisApixaban | 54 | $33,287 |
| FarxigaDapagliflozin Propanediol | 37 | $26,375 |
| TrulicityDulaglutide | 22 | $21,786 |
| MyrbetriqMirabegron | 45 | $21,502 |
| VraylarCariprazine Hcl | 12 | $18,343 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,725 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $12,126 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $11,846 |
| Bydureon BciseExenatide Microspheres | 13 | $10,793 |
| Gabapentin | 192 | $5,494 |
| KonvomepOmeprazole/Sodium Bicarbonate | 12 | $4,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $111 | $83,39787 claims |
| Novo NordiskOzempic | $186 | $72,92362 claims |
| Johnson & JohnsonXarelto | $41 | $55,14966 claims |
| GSKTrelegy Ellipta | $13 | $52,98271 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $60 | $39,10058 claims |
| PfizerEliquis | $180 | $33,28754 claims |
| Lilly USA, LLCTrulicity, Humalog Mix 75-25 | $27 | $23,06438 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $21,50245 claims |
| AbbVieVraylar, Synthroid | $568 | $20,01544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 medical providers in Nebraska.
Other medical in Beatrice
- Stacy LewandowskiBeatrice$1K
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Kelly HooverOmaha$16K
- Lyndsey DegenhardtElkhorn$12K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Shannon BusterPapillion$8K
- Jay ArthurLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.